CA2067194A1 - Cell-free synthesis and isolation of novel genes and polypeptides - Google Patents

Cell-free synthesis and isolation of novel genes and polypeptides

Info

Publication number
CA2067194A1
CA2067194A1 CA002067194A CA2067194A CA2067194A1 CA 2067194 A1 CA2067194 A1 CA 2067194A1 CA 002067194 A CA002067194 A CA 002067194A CA 2067194 A CA2067194 A CA 2067194A CA 2067194 A1 CA2067194 A1 CA 2067194A1
Authority
CA
Canada
Prior art keywords
polypeptides
isolation
cell
free synthesis
novel genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002067194A
Other languages
French (fr)
Other versions
CA2067194C (en
Inventor
Glenn Kawasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Optein Inc
Original Assignee
Glenn Kawasaki
Optein Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenn Kawasaki, Optein Inc. filed Critical Glenn Kawasaki
Publication of CA2067194A1 publication Critical patent/CA2067194A1/en
Application granted granted Critical
Publication of CA2067194C publication Critical patent/CA2067194C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6867—Replicase-based amplification, e.g. using Q-beta replicase

Abstract

A method for the cell-free synthesis and isolation of novel genes and polypeptides is provided. Within one embodiment, an expression unit is constructed onto which semi-random nucleotide sequences are attached. The semi-random nucleotide se-quences are first transcribed to produce RNA, and then translated under conditions such that polysomes are produced. Poly-somes which bind to a substance of interest are then isolated and disrupted;
and the released mRNA is recovered. The mRNA is used to construct cDNA which is expressed to produce novel polypeptides.
CA002067194A 1989-10-05 1990-10-04 Cell-free synthesis and isolation of novel genes and polypeptides Expired - Lifetime CA2067194C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41735789A 1989-10-05 1989-10-05
US417,357 1989-10-05
PCT/US1990/005682 WO1991005058A1 (en) 1989-10-05 1990-10-04 Cell-free synthesis and isolation of novel genes and polypeptides

Publications (2)

Publication Number Publication Date
CA2067194A1 true CA2067194A1 (en) 1991-04-06
CA2067194C CA2067194C (en) 2003-03-18

Family

ID=23653670

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002067194A Expired - Lifetime CA2067194C (en) 1989-10-05 1990-10-04 Cell-free synthesis and isolation of novel genes and polypeptides

Country Status (11)

Country Link
US (2) US5658754A (en)
EP (1) EP0494955B1 (en)
JP (2) JP3127158B2 (en)
KR (3) KR0185192B1 (en)
AT (1) ATE168416T1 (en)
AU (1) AU638762B2 (en)
CA (1) CA2067194C (en)
DE (1) DE69032483T2 (en)
DK (1) DK0494955T3 (en)
ES (1) ES2118066T3 (en)
WO (1) WO1991005058A1 (en)

Families Citing this family (344)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
DE4112440C1 (en) * 1991-04-16 1992-10-22 Diagen Institut Fuer Molekularbiologische Diagnostik Gmbh, 4000 Duesseldorf, De
US5795747A (en) * 1991-04-16 1998-08-18 Evotec Biosystems Gmbh Process for manufacturing new biopolymers
AU2313392A (en) * 1991-08-01 1993-03-02 University Research Corporation Systematic polypeptide evolution by reverse translation
US5783384A (en) * 1992-01-13 1998-07-21 President And Fellows Of Harvard College Selection of binding-molecules
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
AU4843893A (en) * 1992-09-02 1994-03-29 Scripps Research Institute, The Coupled isothermal polynucleotide amplification and translation system
AU8124694A (en) * 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5525734A (en) * 1994-06-22 1996-06-11 Affymax Technologies N.V. Methods for synthesizing diverse collections of pyrrolidine compounds
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
JPH10506463A (en) * 1994-09-21 1998-06-23 サイトーゲン コーポレーション Antigen-binding peptide (abtide) from peptide library
EP0800526B1 (en) * 1994-12-30 2003-03-26 Chiron Corporation Method for the controlled synthesis of polynucleotide mixtures which encode desired mixtures of peptides
US6341256B1 (en) 1995-03-31 2002-01-22 Curagen Corporation Consensus configurational bias Monte Carlo method and system for pharmacophore structure determination
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997045538A1 (en) * 1996-05-31 1997-12-04 Medigene Ag Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
US6875620B1 (en) * 1996-10-31 2005-04-05 Agilent Technologies, Inc. Tiling process for constructing a chemical array
CN1238366C (en) 1997-01-21 2006-01-25 综合医院公司 Selection of proteins using RNA-protein fusions
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US8207093B2 (en) 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
GB2338237B (en) * 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9703369D0 (en) * 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
DE69834032T2 (en) 1997-04-23 2006-12-07 Universität Zürich METHOD OF DETECTING NUCLEIC ACID MOLECULES COPYING FOR (POLY) PEPTIDES THAT INTERACT WITH TARGET MOLECULES
CA2792122C (en) 1997-07-07 2015-09-08 Medical Research Council In vitro sorting method
WO1999005256A2 (en) * 1997-07-24 1999-02-04 President And Fellows Of Harvard College Method for cloning secreted proteins
JP4524445B2 (en) * 1997-09-03 2010-08-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Protein screening method
US6927025B1 (en) 1997-09-03 2005-08-09 Biovation Limited Methods for protein screening
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ATE525477T1 (en) 1998-03-30 2011-10-15 Northwest Biotherapeutics Inc THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF CXCR-4 IN TUMORGENESIS
IL138668A0 (en) * 1998-04-03 2001-10-31 Phylos Inc Addressable protein arrays
US6440695B1 (en) * 1998-04-17 2002-08-27 Whitehead Institute For Biomedical Research Method for producing diverse libraries of encoded polypeptides
US20030170820A1 (en) * 1998-05-08 2003-09-11 Gregory Coia Continuous in- vitro evolution
US6562622B1 (en) * 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
WO2000001849A1 (en) * 1998-07-02 2000-01-13 Invitro Diagnostics, Inc. Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule
US20100130368A1 (en) * 1998-07-30 2010-05-27 Shankar Balasubramanian Method and system for sequencing polynucleotides
US6787308B2 (en) * 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
US20040106110A1 (en) * 1998-07-30 2004-06-03 Solexa, Ltd. Preparation of polynucleotide arrays
US20030022207A1 (en) * 1998-10-16 2003-01-30 Solexa, Ltd. Arrayed polynucleotides and their use in genome analysis
US20040002101A1 (en) * 1998-08-12 2004-01-01 Proteus S.A. Method and kit for discovering nucleic acids that encode desired functions
US6602685B1 (en) 1998-08-17 2003-08-05 Phylos, Inc. Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
EP1105516A4 (en) * 1998-08-17 2002-01-09 Phylos Inc Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular rna-protein fusion formation
US20060088846A1 (en) 1998-08-28 2006-04-27 Michele Pagano Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
PT1137812E (en) 1998-12-02 2007-05-31 Adnexus Therapeutics Inc Dna-protein fusions and uses thereof
CA2669512A1 (en) 1999-03-25 2000-09-28 Abbott Gmbh & Co. Kg Human antibodies that bind human il-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU5011400A (en) 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in t cells
US6623926B1 (en) 1999-06-01 2003-09-23 Phylos, Inc. Methods for producing 5′-nucleic acid-protein conjugates
US20030091999A1 (en) * 1999-10-01 2003-05-15 Zhongping Yu Compositions and methods for identifying polypeptides and nucleic acid molecules
JP2003520050A (en) 2000-01-24 2003-07-02 フィロス インク． Sensitive multiplexed diagnostic assays for protein analysis
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
CA2402452A1 (en) * 2000-03-31 2001-10-11 Cambridge Antibody Technology Limited Improvements to ribosome display
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin fusion proteins
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1339746A2 (en) 2000-08-18 2003-09-03 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)
DK1332209T3 (en) 2000-09-08 2010-03-29 Univ Zuerich Collections of repeat proteins containing repeat modules
JP4723713B2 (en) * 2000-09-25 2011-07-13 トヨタ自動車株式会社 Screening method for potential translational regulator of mRNA
US20040091509A1 (en) * 2000-12-14 2004-05-13 Avon Products, Inc. Skin care composition that mediates cell to cell communication
KR100401296B1 (en) * 2000-12-27 2003-10-11 드림바이오젠 주식회사 Protein Muteins Modified By Modifying Materials And Method For Producing The Same
JP4061043B2 (en) 2000-12-28 2008-03-12 株式会社ポストゲノム研究所 Method for producing peptide etc. by in vitro transcription / translation system
CA2441820C (en) 2001-03-19 2014-01-07 President And Fellows Of Harvard College Evolving new molecular function
EP1249499A1 (en) * 2001-04-10 2002-10-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method and device for the determination and selection of molecule-molecule interactions
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
NZ530098A (en) 2001-06-20 2006-02-24 Nuevolution As Templated molecules and methods for using such molecules
US7727713B2 (en) 2001-06-20 2010-06-01 Nuevolution A/S Templated molecules and methods for using such molecules
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
DK1440083T3 (en) 2001-10-25 2013-03-25 Medical Res Council MOLECULES
GB0126887D0 (en) * 2001-11-08 2002-01-02 Univ London Method for producing and identifying soluble protein domains
GB0127564D0 (en) 2001-11-16 2002-01-09 Medical Res Council Emulsion compositions
US20030162209A1 (en) * 2001-12-19 2003-08-28 George Martin PCR based high throughput polypeptide screening
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20030166010A1 (en) * 2002-02-25 2003-09-04 Affholter Joseph A. Custom ligand design for biomolecular filtration and purification for bioseperation
DK1487978T3 (en) 2002-03-15 2009-03-23 Nuevolution As Improved method for synthesis of template molecules
EP1572927A4 (en) 2002-04-08 2007-10-17 Pioneer Hi Bred Int Enhanced silk exsertion under stress
EP1503780B1 (en) 2002-05-10 2009-08-26 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated pmepa1 gene and methods of using the same to inhibit cancer cell growth
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
WO2003106631A2 (en) * 2002-06-12 2003-12-24 Ambion, Inc. Methods and compositions relating to labeled rna molecules that reduce gene expression
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003247266A1 (en) 2002-08-01 2004-02-23 Nuevolution A/S Multi-step synthesis of templated molecules
AU2003263937B2 (en) 2002-08-19 2010-04-01 The President And Fellows Of Harvard College Evolving new molecular function
KR101051245B1 (en) 2002-09-06 2011-07-21 이소제니카 리미티드 In Vitro Peptide Expression Libraries
BR0314155A (en) 2002-09-09 2005-07-05 Arbor Vita Corp Methods to Diagnose Cervical Cancer
EP1545762A2 (en) 2002-09-27 2005-06-29 Carlsberg A/S Spatially encoded polymer matrix
DK2348124T3 (en) 2002-10-30 2014-03-10 Nuevolution As Synthesis of a bifunctional complex
WO2004042074A2 (en) * 2002-11-04 2004-05-21 Icogenex Corporation Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
CA2504870A1 (en) * 2002-11-04 2004-05-21 Bioarctic Neuroscience Ab Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004056994A2 (en) 2002-12-19 2004-07-08 Nuevolution A/S Quasirandom structure and function guided synthesis methods
WO2004060791A1 (en) * 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
AU2004254552B2 (en) 2003-01-29 2008-04-24 454 Life Sciences Corporation Methods of amplifying and sequencing nucleic acids
US20070026397A1 (en) 2003-02-21 2007-02-01 Nuevolution A/S Method for producing second-generation library
DK1608748T3 (en) 2003-03-20 2009-06-29 Nuevolution As Ligation coding of small molecules
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP2918595B1 (en) 2003-07-05 2019-12-11 The Johns-Hopkins University Method and compositions for detection and enumeration of genetic variations
US7585815B2 (en) * 2003-07-24 2009-09-08 Lawrence Livermore National Security, Llc High throughput protein production screening
DK1664343T3 (en) 2003-09-09 2014-08-11 Integrigen Inc METHODS AND COMPOSITIONS FOR GENERATING CHIMELY HUMAN ANTIBODY GENES
WO2005026387A1 (en) 2003-09-18 2005-03-24 Nuevolution A/S A method for obtaining structural information concerning an encoded molecule and method for selecting compounds
EP1663199B1 (en) * 2003-09-25 2013-04-03 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
US7972994B2 (en) 2003-12-17 2011-07-05 Glaxosmithkline Llc Methods for synthesis of encoded libraries
WO2005058479A2 (en) 2003-12-17 2005-06-30 Praecis Pharmaceuticals, Inc. Methods for synthesis of encoded libraries
WO2005061548A1 (en) 2003-12-23 2005-07-07 Nono Inc. Polypeptides for modulating binding of trp channel proteins and trp-associated proteins.
EP1730277B1 (en) 2004-03-22 2009-10-28 Nuevolution A/S Ligational encoding using building block oligonucleotides
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
EP2270196B1 (en) 2004-05-11 2016-04-20 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (en) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
WO2006018850A2 (en) 2004-08-19 2006-02-23 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (en) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals Production of polypeptides
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7786086B2 (en) 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
RU2401842C2 (en) 2004-10-08 2010-10-20 Домантис Лимитед Antagonists and method of using said antagonists
KR100730875B1 (en) 2004-12-07 2007-06-20 가부시키가이샤 시마즈세이사쿠쇼 DNA fragment to promote translation reaction and method for cell-free system protein synthesis using the same
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
JO3058B1 (en) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
WO2006123445A1 (en) * 2005-05-18 2006-11-23 Kyoto University Method of displaying protein
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
WO2007005605A2 (en) 2005-07-01 2007-01-11 Washington University In St. Louis Phosphospecific chemokine receptor antibodies
WO2007011722A2 (en) 2005-07-15 2007-01-25 President And Fellows Of Harvard College Reaction discovery system
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
WO2007053358A2 (en) 2005-10-28 2007-05-10 Praecis Pharmaceuticals, Inc. Methods for identifying compounds of interest using encoded libraries
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
EP2341140B1 (en) 2005-12-01 2017-07-19 Nuevolution A/S Enzymatic encoding methods for efficient synthesis of large libraries
RS53685B1 (en) 2005-12-29 2015-04-30 Janssen Biotech Inc. Human anti-il-23 antibodies, compositions, methods and uses
EP2363205A3 (en) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors
WO2007111661A2 (en) 2006-03-20 2007-10-04 Xoma Technology Ltd. Human antibodies specific for gastrin materials and methods
US7749957B2 (en) 2006-04-06 2010-07-06 E.I. Du Pont De Nemours And Company Clay-binding peptides and methods of use
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2530168B1 (en) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Microfluidic Devices
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
DK2043671T3 (en) 2006-07-11 2020-06-15 Nono Inc PEPTID AND COMPOSITION THEREOF USED FOR TREATMENT OF FEBRUARY CASES
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
EP2433635A1 (en) 2006-11-10 2012-03-28 Massachusetts Institute Of Technology PAK Modulators
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
KR20150038227A (en) 2007-01-16 2015-04-08 애브비 인코포레이티드 Methods for treating psoriasis
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
CN101679507A (en) * 2007-03-29 2010-03-24 艾博特公司 crystalline anti-human il-12 antibodies
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
EP2182943B1 (en) 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US7678883B2 (en) * 2007-07-25 2010-03-16 E.I. Du Pont De Nemours And Company Solubility tags for the expression and purification of bioactive peptides
US7951559B2 (en) * 2007-07-25 2011-05-31 E.I. Du Pont De Nemours And Company Recombinant peptide production using a cross-linkable solubility tag
US7829311B2 (en) 2007-07-25 2010-11-09 E.I. Du Pont De Nemours And Company Ketosteroid isomerase inclusion body tag engineered to be acid-resistant by replacing aspartates with glutamate
US7794963B2 (en) 2007-11-02 2010-09-14 E.I. Du Pont De Nemours And Company Use of tetracysteine tags in fluorescence-activated cell sorting analysis of prokaryotic cells producing peptides or proteins
CN101932712B (en) 2007-11-20 2014-05-14 先锋国际良种公司 Maize ethylene signaling genes and modulation of same for improved stress tolerance in plants
PL2391650T3 (en) 2007-12-20 2015-03-31 Xoma Us Llc Methods for the treatment of gout
BRPI0908715A2 (en) 2008-03-18 2016-05-03 Abbott Lab Methods for psoriasis treatment
GB0806562D0 (en) 2008-04-10 2008-05-14 Fermentas Uab Production of nucleic acid
JP2010043063A (en) 2008-05-09 2010-02-25 Agency For Science Technology & Research Diagnosis and treatment of kawasaki disease
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
EP3629022A1 (en) 2008-07-25 2020-04-01 Richard W. Wagner Protein screening methods
WO2010017598A1 (en) 2008-08-14 2010-02-18 Arana Therapeutics Limited Anti-il-12/il-23 antibodies
JP2012503983A (en) * 2008-09-26 2012-02-16 ワイス・エルエルシー Compatible display vector system
JP2012503982A (en) * 2008-09-26 2012-02-16 ワイス・エルエルシー Compatible display vector system
MX2011004550A (en) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Fibronectin type iii domain based scaffold compositions, methods and uses.
AU2009313560B2 (en) 2008-11-07 2016-04-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
US20100158846A1 (en) * 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Hair-binding peptides
US20100158822A1 (en) * 2008-12-18 2010-06-24 E .I. Du Pont De Nemours And Company Peptides that bind to silica-coated particles
US20100158837A1 (en) 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Iron oxide-binding peptides
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
JP2012513464A (en) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Phosphodiesterase inhibitors and uses thereof
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
EP3415235A1 (en) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation of microfluidic droplets
US8481678B2 (en) 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
US20100247590A1 (en) * 2009-03-30 2010-09-30 Johnson & Johnson Peptide-Based Systems For Delivery Of Cosmetic Agents
US20110035843A1 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
KR101161622B1 (en) * 2009-08-31 2012-07-04 헬릭스 주식회사 DNA fragment to promote translation efficiency and recombinant vectors containing the same
MX2012003138A (en) * 2009-09-14 2012-07-04 Abbott Lab Y Abbott Gmbh & Co Kg Methods for treating psoriasis.
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
DK2488867T3 (en) 2009-10-14 2020-11-09 Janssen Biotech Inc PROCEDURES FOR AFFINITY MATURE OF ANTIBODIES
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
IL201999A (en) 2009-11-08 2017-10-31 Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel Knock-out mouse of the mo-1 gene, a gene associated with morbid obesity
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
EP2509590B1 (en) 2009-12-10 2019-10-30 The Trustees of Columbia University in the City of New York Histone acetyltransferase activators and uses thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
EP2534267B1 (en) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digital analyte analysis
WO2011111832A1 (en) 2010-03-11 2011-09-15 独立行政法人理化学研究所 Method for selecting polypeptide sequence, metal oxide or silicon containing compound binding peptide and use thereof
LT2558577T (en) 2010-04-16 2019-03-12 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
MX339126B (en) 2010-04-30 2016-05-11 Janssen Biotech Inc Stabilized fibronectin domain compositions, methods and uses.
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
EP2614073B1 (en) 2010-09-07 2018-03-14 Technische Universität München Recombinant bacterial lipocalin blc and uses thereof
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
JP6616057B2 (en) 2010-12-22 2019-12-04 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Histone acetyltransferase modulators and uses thereof
DE102010056289A1 (en) 2010-12-24 2012-06-28 Geneart Ag Process for the preparation of reading frame correct fragment libraries
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
JP5948673B2 (en) 2011-03-10 2016-07-06 ジーンフロンティア株式会社 COMPOSITION FOR PROTEIN SYNTHESIS WITH REDUCED LIPO POLUCHIsaccharide CONTENT AND METHOD FOR PRODUCING PROTEIN USING THE COMPOSITION
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20120301904A1 (en) * 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
JP6057297B2 (en) 2011-05-23 2017-01-11 国立研究開発法人理化学研究所 Nucleic acid construct, nucleic acid-protein complex, and use thereof
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP3709018A1 (en) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Microfluidic apparatus for identifying components of a chemical reaction
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
BR112014005104A2 (en) 2011-09-02 2017-07-04 Salk Inst For Biological Studi camkii, ip3r, calcineurin, p38 and mk2 / 3 inhibitors to treat bind metabolic disorders of obesity
EP3275461A1 (en) 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
EP4151785A1 (en) 2011-09-27 2023-03-22 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
KR20170021919A (en) 2011-10-21 2017-02-28 화이자 인코포레이티드 Addition of iron to improve cell culture
CN103906835A (en) 2011-10-25 2014-07-02 先锋国际良种公司 Methods to alter plant cell wall composition for improved biofuel production and silage digestibility
EP2794657B1 (en) 2011-12-19 2017-10-11 Xoma (Us) Llc Methods for treating acne
PT2830662T (en) 2012-03-29 2018-11-29 Univ Columbia Methods for treating hair loss disorders
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2657334B1 (en) 2012-04-26 2016-07-06 GeneFrontier Corporation Efficient method for displaying protein multimer
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
GB201214029D0 (en) * 2012-08-07 2012-09-19 Queen Mary & Westfield College method
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
SI3447069T1 (en) 2012-11-21 2021-02-26 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
WO2014152507A2 (en) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Modulation of acc deaminase expression
WO2014152027A1 (en) * 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
LT3019619T (en) 2013-07-11 2021-12-10 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
KR102478402B1 (en) 2013-10-14 2022-12-15 얀센 바이오테크 인코포레이티드 Cysteine engineered fibronectin type iii domain binding molecules
US9309314B2 (en) 2013-12-03 2016-04-12 Agency For Science, Technology And Research (A*Star) Polypeptides, nucleic acids and uses thereof
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
CA2935378C (en) 2013-12-24 2023-04-18 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10544395B2 (en) 2014-03-19 2020-01-28 Pfizer Inc. Method of cell culture
US10106579B2 (en) 2014-06-12 2018-10-23 Ra Pharmaceuticals, Inc. Modulation of complement activity
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CN114057857A (en) 2014-06-20 2022-02-18 豪夫迈·罗氏有限公司 CHAGASIN-based scaffold compositions, methods and uses
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
EP3265491A1 (en) 2015-03-03 2018-01-10 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
ES2820768T3 (en) 2015-04-03 2021-04-22 Xoma Technology Ltd Cancer treatment using TGF-beta and PD-1 inhibitors
CN116063543A (en) 2015-04-24 2023-05-05 豪夫迈·罗氏有限公司 Multispecific antigen-binding proteins
EA201792441A2 (en) 2015-05-06 2018-06-29 Янссен Байотек, Инк. FIBRONECTIN TYPE III DOMAINS CONNECTING WITH A PROSTATSPECIFIC MEMBRANE ANTIGEN
CN107922497B (en) 2015-06-24 2022-04-12 詹森药业有限公司 anti-VISTA antibodies and fragments
EP3331562A2 (en) 2015-08-06 2018-06-13 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
CA3214798A1 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
DK3389692T3 (en) 2015-12-16 2020-03-30 Ra Pharmaceuticals Inc MODULATORS OF COMPLEMENT ACTIVITY
TWI756204B (en) 2016-02-12 2022-03-01 比利時商楊森製藥公司 Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017172771A2 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
AU2017247701B2 (en) 2016-04-05 2022-11-10 Pfizer Inc. Cell culture process
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3463430A4 (en) 2016-06-03 2020-02-12 Janssen Biotech, Inc. Serum albumin-binding fibronectin type iii domains
MX2018016185A (en) 2016-06-21 2019-03-28 Janssen Biotech Inc Cysteine engineered fibronectin type iii domain binding molecules.
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
EP3484927A1 (en) 2016-07-15 2019-05-22 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
JP2019524721A (en) 2016-07-15 2019-09-05 ポセイダ セラピューティクス， インコーポレイテッド Chimeric antigen receptor and method of use
EP3490600A1 (en) 2016-08-01 2019-06-05 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
CN109715199A (en) 2016-09-14 2019-05-03 詹森生物科技公司 Chimeric antigen receptor and application thereof comprising BCMA specificity type III fibronectin domain
CA3038679A1 (en) 2016-09-28 2018-04-05 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
CA3037961A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
KR20190078648A (en) 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 Methods for treating psoriasis with anti-IL23 specific antibodies
MX2019006527A (en) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Modulators of complement activity.
JP7104703B2 (en) 2016-12-14 2022-07-21 ヤンセン バイオテツク，インコーポレーテツド CD8A-binding fibronectin type III domain
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3354736B1 (en) * 2017-01-25 2020-07-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Promoter construct for cell-free protein synthesis
EP3573658A4 (en) 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
JP2020506947A (en) 2017-02-07 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
SG11201908418RA (en) 2017-03-13 2019-10-30 Poseida Therapeutics Inc Compositions and methods for selective elimination and replacement of hematopoietic stem cells
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
EP3679145A2 (en) 2017-09-08 2020-07-15 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
JP2020533983A (en) 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Online biomass capacitance monitoring during large-scale production of the polypeptide of interest
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
KR20200129125A (en) 2018-03-05 2020-11-17 얀센 바이오테크 인코포레이티드 How to treat Crohn's disease with anti-IL23 specific antibodies
CN111902160A (en) 2018-03-16 2020-11-06 百时美施贵宝公司 Metabolic enzyme activity and disulfide bond reduction during protein production
US20190345245A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
SI3883606T1 (en) 2018-09-24 2023-10-30 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
US11548941B2 (en) 2018-11-20 2023-01-10 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
JP2022513702A (en) 2018-12-06 2022-02-09 ファイザー・インク Cells with reduced inhibitor production and how to use them
EP3897722A4 (en) 2018-12-18 2022-09-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
CA3124103A1 (en) 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
EP3911676A1 (en) 2019-01-15 2021-11-24 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
KR20210118878A (en) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 Anti-TNF antibody composition for use in a method of treating psoriatic arthritis
SG11202107720UA (en) 2019-01-31 2021-08-30 Agency Science Tech & Res Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
MA55283A (en) 2019-03-14 2022-01-19 Janssen Biotech Inc METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS
KR20210141998A (en) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 Method of making anti-TNF antibody composition
MA55282A (en) 2019-03-14 2022-01-19 Janssen Biotech Inc MANUFACTURING METHODS FOR THE PRODUCTION OF ANTI-TNF ANTIBODY COMPOSITIONS
JP2022525145A (en) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド A production method for producing an anti-IL12 / IL23 antibody composition.
EA202192459A1 (en) 2019-03-18 2021-11-25 Янссен Байотек, Инк. METHOD FOR TREATMENT OF PSORIASIS WITH ANTIBODY TO IL12 / IL23 IN CHILDREN
WO2020227554A1 (en) 2019-05-09 2020-11-12 Genentech, Inc. Methods of making antibodies
KR20220012883A (en) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 A method of treating inflammatory bowel disease with a combination therapy of IL-23 and an antibody against TNF alpha
EP3976648A1 (en) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
CA3142580A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
US20220372105A1 (en) 2019-09-05 2022-11-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
CA3162246A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
WO2021183795A1 (en) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CN115996747A (en) 2020-04-14 2023-04-21 波赛达治疗公司 Compositions and methods for treating cancer
US20240000969A1 (en) 2020-10-21 2024-01-04 Poseida Therapeutics San Diego Compositions and methods for delivery of nucleic acids
AU2022232007A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
CA3212729A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
KR20240032991A (en) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 Manufacturing Methods for Producing Anti-TNF Antibody Compositions
US20230038355A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023060088A1 (en) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710464A (en) * 1984-09-27 1987-12-01 Eli Lilly And Company Transcription terminators
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ZA862335B (en) * 1985-03-28 1987-11-25 Cetus Corp Process for amplifying nucleic acid sequences
CH0229046H1 (en) * 1985-03-30 1998-07-15 Stuart Alan Kauffman METHOD FOR OBTAINING DNA, RNA, PEPTIDES, POLYPEPTINIQUE. DES OR PROTEINS BY MEANS OF A DNA RECOMBINANT TECH
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences

Also Published As

Publication number Publication date
ATE168416T1 (en) 1998-08-15
WO1991005058A1 (en) 1991-04-18
EP0494955A4 (en) 1992-08-12
DK0494955T3 (en) 1998-10-26
KR100204360B1 (en) 1999-06-15
US5643768A (en) 1997-07-01
KR0185192B1 (en) 1999-04-01
CA2067194C (en) 2003-03-18
ES2118066T3 (en) 1998-09-16
EP0494955B1 (en) 1998-07-15
JP3127158B2 (en) 2001-01-22
DE69032483T2 (en) 1998-11-26
AU638762B2 (en) 1993-07-08
US5658754A (en) 1997-08-19
KR920703839A (en) 1992-12-18
DE69032483D1 (en) 1998-08-20
KR100204359B1 (en) 1999-06-15
AU6537390A (en) 1991-04-28
EP0494955A1 (en) 1992-07-22
JP2001078787A (en) 2001-03-27
JPH05503000A (en) 1993-05-27

Similar Documents

Publication Publication Date Title
CA2067194A1 (en) Cell-free synthesis and isolation of novel genes and polypeptides
EP0088195A3 (en) Messenger rna, production and use thereof
EP0330191A3 (en) DNA encoding CD40
AU8363698A (en) New chemical compound suitable for use as an explosive, intermediate and method for preparing the compound
CA2284750A1 (en) Steroid sulfamates, method for the production and use thereof
AU4714489A (en) Assay of sequences using amplified genes
AU587308B2 (en) Process for the production of synthesis gas
DK1792982T3 (en) Codon-optimized phosphatase and its expression in yeast
WO1997027276A3 (en) Nucleic acids encoding polypeptides having absidia lipase activity
EP0879822A3 (en) Method for preparation of alkenylsilanes
JPS5739798A (en) Prepartion of deacetylcephalosporin c or its salt and acetyl esterase used for it
CA2135853A1 (en) Process for large-scale preparation of 2',3'-didehydro-2',3'-dideoxynucleosides
AU2333897A (en) Alpha2 subunit of prolyl-4-hydroxylase nucleic acid sequences encoding such subunit and methods for producing the same
WO1999067218A3 (en) Method of preparing 5- or 8-bromoisoquinoline derivatives
AU7162791A (en) Novel system for isolating and producing new genes, gene products and dna sequences
ATE256676T1 (en) METHOD FOR PRODUCING 5-(ALFA-HYDROXYALKYL)BENZO-(1,3)DIOXOLANS
EP0855388A3 (en) Method for making intermediates useful in synthesis of retroviral protease inhibitors
Barco et al. Enantioselective formal synthesis of Acromelic acid A via tandem Michael reaction methodoligy
AU6330694A (en) Process for the enantioselective synthesis of intermediates used in the preparation of physostigmine
JPS5329994A (en) Continuous reaction using enzymes or microorganisms
WO1995023795A3 (en) Process for preparing polyfluorooxetanes
AU1437588A (en) New process for the synthesis of the alpha-(1-methyl-ethyl)- 3,4-dimethoxybenzene-acetonitrile
Kulikov Influence of anisotropy on the stress state of multilayer reinforced shells
AU9017498A (en) Plant genes encoding dr1 and drap1, a global repressor complex of transcription
AU4279289A (en) An improved process for the recovery of valuable metals

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry